*Include 3 bullets (< 30 words total) per slide – the most important messages associated with the particular slide*

Team name: ME Therapeutics Inc.

Date updated: September 1, 2019

|  |  |
| --- | --- |
| S1: Title& Elevator Pitch/Headline | * IMPROVING IMMUNO-ONCOLOGY For COLORECTAL CANCER
* IO has revolutionized cancer treatment but doesn’t work in colon cancer
* Our new drug can make colon cancer responsive to IO
 |
| S2: The problem | * Current immunotherapy has proven effective against some late stage cancers
* Many tumor types including CRC are resistant to current immunotherapies
* Immunosuppressive cells make these tumors resistant to IO therapy
 |
| S3: The solution  | * Current IO therapy works by stimulating T cells to attack cancer
* Knocking down immunosuppressive cells can improve IO therapies
* Synergy with new drugs is required to improve IO for cancer
 |
| S4: Product (how it addresses the problem) | * G-CSF expands MDSCs to create an immunosuppressive tumor environment
* Our drug decreases the activity of MDSCs by neutralizing G-CSF
* Removing MDSCs will enhance T cell function against cancer
 |
| S5: First Application | * Colon cancer has a high unmet need because IO is ineffective
* G-CSF is highly expressed and promotes an immunosuppressive tumor environment
* High G-CSF expression is associated with poor prognosis
 |
| S6: Technology | * Our drug reduces MDSCs and increases T cells in colon cancer
* Our drug decreases tumor counts and tumor size

Our drug is ready to test alone or in combination therapy  |
| S7:Competing approaches | * Current IO therapy is only effective for 5% of patients
* Crowded pipeline with many combination therapies being tested
* We have selected a unique approach targeting G-CSF
 |
| S8:Team | * Founders have background in industry, academia and cancer immunology
* We have 2 PhD scientists and rent space at UBC
* Member of MIT IDEA2 Startup Incubator Program
 |
| S9:Traction & summary | * We filed worldwide patents on 2 lead antibodies and own IP
* Science validated by grant funding and support BC Cancer doctors
* Blocking G-CSF will improve IO effectiveness against CRC
 |